SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

FNMA and FMCC are seeing intense volatility driven by speculation around potential GSE reform and government exit strategies, further fueled by high-profile endorsements from investors like Bill Ackman and Michael Burry. While the community remains deeply polarized between bullish long-term holders eyeing potential 10x gains and bearish traders skeptical of political timelines, buying interest has picked up significantly as investors monitor for news out of Washington.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the Materials and Magnetics segments. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is trending as investors digest a mixed earnings report that highlighted a pivot away from the Chinese market and the acceleration of a government-backed domestic magnet supply chain. The community is actively debating the long-term potential of the firm's '10X' facility and its strategic partnerships with major tech and defense entities, while some traders closely monitor the stock's volatility in response to broader geopolitical tensions.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is experiencing intense volatility as investors weigh strong quarterly revenue growth and aggressive expansion via recent acquisitions against concerns over dilution and persistent profitability challenges. The stock remains a battleground for retail traders, with the community actively debating whether the current price represents a tactical entry opportunity or an overvalued bubble susceptible to a sharp reversal.

Phreesia, Inc. engages in the provision of patient check-in solutions for medical practices. The firm offers appointments, clinical support, integration, registration, patient activation, analytics and reports, revenue cycle, patient surveys, and privacy and security products. Its solutions include health systems, multi-specialty, and federally qualified health centers (FQHCs). The company was founded by Chaim Indig and Evan Roberts in January 2005 and is headquartered in Wilmington, DE.

Phreesia Inc

Phreesia shares are reeling after the company lowered its fiscal 2027 revenue outlook, triggering significant investor disappointment and community concerns regarding the firm's growth trajectory. The stock is facing heavy downward pressure as traders debate whether the current selloff represents a deep-value opportunity or a sign of broader struggles within the SaaS sector.

Maul Coin

Maul Coin is generating significant retail buzz as a community-driven project, with supporters actively coordinating to push the token toward trending status and seeking improved visibility on trading platforms. The conversation is dominated by early investors urging others to hold through market volatility while comparing the token's potential to other viral meme coins.

Freddie Mac engages in the provision of housing finance system solutions. It operates through the Single-Family and Multifamily segments. The Single-Family segment is involved in purchase, securitization, and guarantee of single-family loans, investments, and management of single-family mortgage credit risk and market risk. The Multifamily segment focuses on purchase, securitization, and guarantee of multifamily loans, investments, securities, and management of multifamily mortgage credit risk and market risk. The company was founded on July 24, 1970 and is headquartered in McLean, VA.

Federal Home Loan Mortgage Corp

Freddie Mac

Freddie Mac (FMCC) and Fannie Mae are trending as investors speculate on a potential path out of government conservatorship, fueled by high-profile endorsements from Bill Ackman and Michael Burry. The community is heavily focused on the prospect of a major relisting on the NYSE, with active discussions debating whether the current market movement represents a fundamental rerating or a high-stakes political trade on future administration policy.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending as investors weigh strong oncology pipeline progress against ongoing concerns regarding high debt levels, patent cliffs, and lukewarm results from its recent weight-loss drug trials. While the community is actively debating the stock's long-term growth potential and dividend stability, current sentiment remains split between those chasing income and those skeptical of the company's aggressive M&A strategy.

Progress Software Corp. engages in the provision of products that develop and deploy mission-critical business applications. Its products and solutions include Chef, Corticon, DataDirect, Developer Tools, Flowmon, Kemp LoadMaster, MarkLogic, MOVEit, OpenEdge, Semaphore, ShareFile, Sitefinity & WhatsUp Gold. The company was founded by Joseph Wright Alsop, Clyde Kessel, and Charles Arthur Ziering in 1981 and is headquartered in Burlington, MA.

Progress Software Corp.

Progress Software is trending as investors weigh strong earnings performance against concerns over Q4 guidance and the integration costs of the recently acquired ShareFile business unit. The community is actively debating the stock's long-term valuation and future growth prospects while navigating heightened volatility surrounding its latest financial results.

NextNav, Inc. engages in development of positioning, navigation, and timing solutions. Its products include NextNav Pinnacle, NextNav 3D, and NextNav TerraPoiNT. The company was founded by Ganesh Pattabiraman and Arun Raghupathy in May 2021 and is headquartered in Reston, VA.

NextNav Inc

NextNav is currently trending as investors monitor regulatory developments for a potential Notice of Proposed Rulemaking (NPRM) regarding its 900 MHz spectrum assets. Community discussion is heavily focused on interpreting recent FCC agenda leaks and technical filings, with many market participants viewing any price weakness as an accumulation opportunity while anticipating a shift in terrestrial PNT (Positioning, Navigation, and Timing) infrastructure.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending following a dramatic management overhaul that saw the removal of CEO Peter Greenleaf and key executives, with board chair Kevin Tang assuming the CEO role while electing to receive no compensation. Investors are actively debating the implications of this shift, with many interpreting the move as a long-awaited catalyst to accelerate a potential acquisition or strategic sale after years of frustration with the company's communication and valuation performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates

Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Lags Revenue Estimates

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates

Shares of Optinose, Inc. (OPTN) rocketed about 55% on Thursday after privately held Paratek Pharmaceuticals <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.optinose.com/news-releases/news-release-details/paratek-pharmaceuticals-acquire-optinose-creating-significant">announced</a> that it would buy the company for up to $330 million.The two companies have entered into a definitive merger agreement, under which Paratek will acquire Optinose and its product XHANCE, a drug-device combination product approved for the treatment of Chronic rhinosinusitis.Paratek will acquire Optinose's outstanding shares for $9 apiece in cash, representing a 50% premium to Optinose’s closing trading price of $6 on March 19, and up to $5 per share in contingent value rights (CVRs) if XHANCE achieves certain net revenue milestones.Paratek said in a statement that the boards of both companies have unanimously approved the transaction. It added that the transaction is expected to close as early as mid-2025, subject to customary closing conditions and approval by Optinose shareholders.Upon completion of the transaction, Optinose will be delisted from the NASDAQ Global market.Following the announcement, Optinose also <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.optinose.com/news-releases/news-release-details/optinose-cancels-fourth-quarter-and-full-year-2024-earnings-call">canceled</a> its earnings call for the fourth quarter of 2024, which was originally scheduled for March 20.Optinose CEO Ramy Mahmoud said that Paratek, with its commercial and medical capabilities, has the potential to increase awareness for Optinose’s XHANCE.“We are excited about the many ways in which this transaction creates opportunities for XHANCE to help more patients achieve better symptom control while creating near- and long-term value for Optinose's shareholders," he said.Paratek, meanwhile, said that the acquisition will help the company expand its portfolio.On Stocktwits, retail investor sentiment flipped from ‘extremely bearish’ to ‘extremely bullish’ (100/100) territory within the past 24 hours, coupled with ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:810/181;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2025_03_20_115139_png_df0e5340e2.webp" alt="Optinose’s Sentiment Meter and Message Volume as of 11:50 a.m. ET on March 20, 2025 | Source: Stocktwits" width="810" height="181"><figcaption>Optinose’s Sentiment Meter and Message Volume as of 11:50 a.m. ET on March 20, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/OPTN">Optinose shares</a> are up over 38% in 2025 but have lost over 60% in the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/geo-stock-rises-on-ice-contract/ch7Nru4RbPQ">GEO Stock Rises On Immigration And Customs Contract With Annualized Revenue Potential Of $70M: Retail’s On The Fence</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail investors on Stocktwits — where Altimmune has over 36,000 followers — have long speculated that the company could be a takeover target. | Image source: Getty Images

Optinose Shares Soar After Merger Agreement With Paratek Pharmaceuticals: Retail Sentiment Takes Flight 

Paratek will acquire Optniose's outstanding shares for $9 apiece in cash, representing a 50% premium to the stock’s closing trading price of $6 on March 19.

Equity

Paratek will acquire Optinose's outstanding shares for $9 apiece in cash, representing a 50% premium to the stock’s closing trading price of $6 on March 19, and up to $5 per share in contingent value rights if XHANCE achieves certain net revenue milestones.


Option Therapeutics Inc

Patrick OShaughnessy - @patrick_oshag on X

Citrini - @Citrini7 on X

Bucco Capital - @buccocapital on X

Joe Weisenthal - @TheStalwart on X

The must-watch individual or show that brings entertainment to finance. This award celebrates the content you look forward to daily - bringing a sharp market edge to engaging discussions. 

Current Price	$9.60
Prev Close	$9.71
Open	$9.67
Dividend Yield	N/A
50-Day Moving Average	N/A
Beta	N/A
Avg. Volume	N/A
PE Ratio	N/A

52-Week High	N/A
52-Week Low	N/A
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

OPTN
OptiNose Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest OPTN News

OPTNOptiNose Inc